Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 8/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | ACACB | O00763 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315251 | 0.86 | ACACB (0.52) | KDM1ANPY1RSLC6A4KCNH2ACACB | |
| SCHEMBL3317082 | 0.84 | EPHX2 (0.45) | ACACBACHE | |
| SCHEMBL3317146 | 0.84 | L3MBTL1 (0.42) | NPY1RSLC6A4TAS1R3TAS1R1 | |
| SCHEMBL3315968 | 0.82 | ADRB2 (0.48) | NPY1RSLC6A4KCNH2RAB9A | |
| SCHEMBL3310959 | 0.79 | PANK3 (0.42) | KDM1A | |
| SCHEMBL22342849 | 0.78 | KDM1A (0.55) | KDM1ANPY1RSLC6A4KCNH2ACACB | |
| SCHEMBL3320853 | 0.77 | DPP4 (0.45) | ACACBMEN1RAB9AKMT2A | |
| SCHEMBL2571281 | 0.77 | HSD17B2 (0.45) | CA1CA2MEN1KMT2A | |
| SCHEMBL3314353 | 0.74 | KDM1A (0.51) | KDM1ANPY1RSLC6A4KCNH2ACACB | |
| SCHEMBL22342837 | 0.74 | GAA (0.62) | KDM1ASLC6A4CA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | KDM1A 3657/4885NPY1R 104/4885SLC6A4 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.